These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Efficacy of insulin Lispro in the control of late postprandial hypoglycemia: comparison with regular human insulin]. Cotticelli G; Bartiromo D; Ciavattone A; Di Leva R; Porcaro G; Nascia S; Mastroianni M; Sannino C; Conti G Minerva Med; 2000; 91(7-8):147-52. PubMed ID: 11155463 [TBL] [Abstract][Full Text] [Related]
43. Comparison of Subcutaneous Regular Insulin and Lispro Insulin in Diabetics Receiving Continuous Nutrition: A Numerical Study. Stull MC; Strilka RJ; Clemens MS; Armen SB J Diabetes Sci Technol; 2015 Jun; 10(1):137-44. PubMed ID: 26134836 [TBL] [Abstract][Full Text] [Related]
44. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Kotsanos JG; Vignati L; Huster W; Andrejasich C; Boggs MB; Jacobson AM; Marrero D; Mathias SD; Patrick D; Zalani S; Anderson J Diabetes Care; 1997 Jun; 20(6):948-58. PubMed ID: 9167105 [TBL] [Abstract][Full Text] [Related]
45. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog). Roper NA; Bilous RW Diabet Med; 1998 Dec; 15(12):1063-4. PubMed ID: 9868982 [TBL] [Abstract][Full Text] [Related]
46. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069 [TBL] [Abstract][Full Text] [Related]
47. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump. Catargi B; Breilh D; Roger P; Tabarin A Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895 [TBL] [Abstract][Full Text] [Related]
48. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro. Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355 [TBL] [Abstract][Full Text] [Related]
49. Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro. Bastyr EJ; Huang Y; Brunelle RL; Vignati L; Cox DJ; Kotsanos JG Diabetes Obes Metab; 2000 Jan; 2(1):39-46. PubMed ID: 11220353 [TBL] [Abstract][Full Text] [Related]
50. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Garg SK; Frias JP; Anil S; Gottlieb PA; MacKenzie T; Jackson WE Endocr Pract; 2003; 9(3):187-93. PubMed ID: 12917059 [TBL] [Abstract][Full Text] [Related]
51. Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Holleman F; van den Brand JJ; Hoven RA; van der Linden JM; van der Tweel I; Hoekstra JB; Erkelens DW Diabetes Care; 1996 Dec; 19(12):1426-9. PubMed ID: 8941477 [TBL] [Abstract][Full Text] [Related]
52. Treatment of adolescents with type 1 diabetes mellitus. Garg S; Chase HP J Pediatr Endocrinol Metab; 2004 May; 17(5):805-6. PubMed ID: 15237718 [No Abstract] [Full Text] [Related]
53. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Jovanovic L; Ilic S; Pettitt DJ; Hugo K; Gutierrez M; Bowsher RR; Bastyr EJ Diabetes Care; 1999 Sep; 22(9):1422-7. PubMed ID: 10480503 [TBL] [Abstract][Full Text] [Related]
54. Insulin analogues and management of diabetes mellitus. Vaidyanathan B; Menon PS Indian J Pediatr; 2000 Jun; 67(6):435-41. PubMed ID: 10932964 [TBL] [Abstract][Full Text] [Related]
55. Insulin lispro (Humalog), a novel fast-acting insulin analogue: guidelines for its practical use. Nobels FR; Hermans MP; De Leeuw I Acta Clin Belg; 1999 Oct; 54(5):246-54. PubMed ID: 10555382 [No Abstract] [Full Text] [Related]
56. Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Cypryk K; Sobczak M; Pertyńska-Marczewska M; Zawodniak-Szałapska M; Szymczak W; Wilczyński J; Lewiński A Med Sci Monit; 2004 Feb; 10(2):PI29-32. PubMed ID: 14737056 [TBL] [Abstract][Full Text] [Related]
57. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Lapolla A; Dalfrà MG; Spezia R; Anichini R; Bonomo M; Bruttomesso D; Di Cianni G; Franzetti I; Galluzzo A; Mello G; Menato G; Napoli A; Noacco G; Parretti E; Santini C; Scaldaferri E; Scaldaferri L; Songini M; Tonutti L; Torlone E; Gentilella R; Rossi A; Valle D Acta Diabetol; 2008 Mar; 45(1):61-6. PubMed ID: 18227964 [TBL] [Abstract][Full Text] [Related]
58. Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. Recasens M; Aguilera E; Morínigo R; Casamitjana R; Nicoletti F; Gomis R; Conget I Diabetes Res Clin Pract; 2003 Jun; 60(3):153-9. PubMed ID: 12757987 [TBL] [Abstract][Full Text] [Related]
59. Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus. Garg SK; Anderson JH; Perry SV; Mackenzie T; Keith P; Jennings MK; Hansen MM; Chase HP Diabet Med; 1999 May; 16(5):384-7. PubMed ID: 10342337 [TBL] [Abstract][Full Text] [Related]
60. A patient with subcutaneous-insulin resistance treated by insulin lispro plus heparin. Tokuyama Y; Nozaki O; Kanatsuka A Diabetes Res Clin Pract; 2001 Dec; 54(3):209-12. PubMed ID: 11689276 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]